HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mayo, L. Articles by Stein, R. Search for Related Content PubMed PubMed Citation Articles by Mayo, L. Articles by Stein, R.

Dual Role of CD38 in Microglial Activation and Activation-Induced Cell Death¹

Lior Mayo^*, Jasmine Jacob-Hirsch, Ninette Amariglio, Gideon Rechavi, Marie-Jo Moutin, Frances E. Lund and Reuven Stein^2,*

^* Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Israel; Department of Pediatric Hematology-Oncology, Safra Children’s Hospital, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The Trudeau Institute, Saranac Lake, NY 12983; and Grenoble Institut des Neurosciences équipe 1, Centre de Recherche Institut National de la Santé et de la Recherche Médicale (Unité 836)-Université Joseph Fourier-Commissariat à l’Energie Atomique-Centre Hospitalier de l’Université, Grenoble, France

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Microglia, the resident immune cells of the CNS, are normally quiescent but become activated after infection or injury. Their properties then change, and they promote both repair and damage processes. The extent of microglial activation is regulated, in part, by activation-induced cell death (AICD). Although many apoptotic aspects of the microglial AICD mechanism have been elucidated, little is known about the connection between the activation step and the death process. Using mouse primary microglial cultures, we show that the ectoenzyme CD38, via its calcium-mobilizing metabolite cyclic-ADP-ribose (cADPR), helps promote microglial activation and AICD induced by LPS plus IFN- (LPS/IFN-), suggesting that CD38 links the two processes. Accordingly, CD38 expression and activity, as well as the intracellular calcium concentration ([Ca²⁺]_i) in the primary microglia were increased by LPS/IFN- treatment. Moreover, CD38 deficiency or treatment with cADPR antagonists conferred partial resistance to LPS/IFN--induced AICD and also reduced [Ca²⁺]_i. Microglial activation, indicated by induced expression of NO synthase-2 mRNA and production of NO, secretion and mRNA expression of TNF- and IL-12 p40, and expression of IL-6 mRNA, was attenuated by CD38 deficiency or cADPR-antagonist treatment. The observed effects of CD38 on microglial activation are probably mediated via a cADPR-dependent increase in [Ca²⁺]_i and the effect on AICD by regulation of NO production. Our results thus suggest that CD38 significantly affects regulation of the amount and function of activated microglia, with important consequences for injury and repair processes in the brain.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Microglia, the resident immune cells of the CNS, are quiescent in the mature brain under physiological conditions. Following acute brain injury, microglia migrate to the damaged sites where they proliferate and become activated (1, 2). Activation is accompanied by morphological changes, up-regulated expression of cell surface proteins (e.g., MHC class II molecules, CD11b, and scavenger receptors), cytokines (e.g., TNF-, IL-6, and IL-12), chemokines (e.g., CCL12), and NO production (3, 4).

Activated microglia can promote both protective and harmful effects. Beneficial effects include removal of cell debris and myelin fragments, buffering of toxic compounds, and secretion of neurotrophins and cytokines capable of supporting survival of injured neurons (5, 6). Microglia can also be beneficial in neurodegenerative diseases, for example, by clearing β-amyloid (7). However, they can also produce and secrete toxic factors, including TNF- and IL-1β and free radicals such as NO (8, 9, 10); accordingly, some authors have postulated that microglial activation participates in the pathogenesis of several neurodegenerative diseases, including Alzheimer’s and Parkinson’s (11, 12, 13). Activated microglia might also be at least partially responsible for secondary damage after traumatic brain injury (14, 15); thus, their numbers and activity need to be strictly regulated. Indeed, following the initial rapid increase in activated microglia after acute brain injury, their numbers gradually decrease (16, 17). Among the mechanisms thought to help control the disappearance of activated microglia after brain damage is their elimination via cell death, termed microglial activation-induced cell death (AICD),³ and observed, for example, in animal models of brain damage and microglial activation (18, 19, 20, 21, 22). Consistent with those observations, treatment with agents known to induce microglial activation, such as LPS and IFN-, induces apoptosis in microglial cell lines and primary cultures (23, 24, 25, 26).

Our group and others have characterized the apoptotic pathways of AICD induced by LPS and IFN- (LPS/IFN-) and demonstrated their mediation via the NO-promoted (24) Bak/Bax-activated mitochondrial gateway (26) and caspase 11 (23). Although these studies have helped to elucidate this AICD mechanism, little is known about the relationship between the activation step and the death process. In this study, we show that CD38, an ectoenzyme that uses β-NAD to generate multiple Ca²⁺-mobilizing metabolites (27, 28, 29), participates in both the activation and the AICD processes of LPS/IFN--treated microglia. The CD38 effects were mediated, at least in part, via cyclic ADP-ribose (cADPR).

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Animals, drugs, and reagents

CD38-deficient mice (Cd38^–/–) (30), backcrossed 12 generations to BALB/cBy mice (31), were obtained from The Trudeau Institute Breeding Facility (Saranac Lake, NY) and were maintained in accordance with all applicable rules and guidelines of the Animal Care and Use Committee of Tel Aviv University.

Reagents used were purchased from Sigma-Aldrich unless indicated otherwise. Mouse IFN- was purchased from R&D Systems; ryanodine was obtained from Calbiochem; actinomycin D (AMD) was obtained from ICN Biomedicals; HBSS was obtained from Biological Industries; DMEM, fura-2 AM, and Pluronic F-127 were obtained from Invitrogen Life Technologies. Nicotinamide 8-bromoadenine dinucleotide N(8-Br-A)D⁺ was prepared as described (32).

Antibodies

Rabbit anti-inducible NO synthetase (iNOS) polyclonal Abs (no. AB1631) were obtained from Chemicon International. Rat anti-caspase-11 (17D9, no. C1354) and mouse anti-β-tubulin mAbs (no. T4026) were purchased from Sigma-Aldrich. PE-conjugated rat anti-CD38 (NIMR-5, no. 1635-09), low endotoxin/azide-free rat anti-CD38 (90, no. 1640-14) mAbs, and low endotoxin/azide-free rat IgG2a isotype control Ab (no. 0117-14) were obtained from Southern Biotechnology Associates; PE-conjugated rat anti-CD11b mAb (M1/70, 101207) was obtained from Biolegend. Purified rat IgG2a anti-mouse monoclonal CD38 Ab (clone NIM-R5) was produced by the Trudeau mAb facility. Secondary Ab F(ab')₂ mouse anti-rat IgG (H+L; no. 212-006-168) was purchased from Jackson ImmunoResearch Laboratories.

Cell culture

The N9 mouse microglial cell line (33) was maintained in DMEM supplemented with 10% FCS (Invitrogen). CD38-expressing (CD38^exp) and nonexpressing (empty vector transfected Ba/F₃ cells (CD38^neg)) Ba/F₃ cells (34) were cultured in RPMI 1640 supplemented with 10% WEHI-3 supernatant (containing IL-3), 10% FCS, nonessential amino acids, sodium pyruvate, L-glutamine, HEPES, 2-ME, and antibiotics. Mouse primary microglia were prepared as previously described (26), with minor modifications. Cerebral cortices from 1- to 3-day-old neonatal BALB/c (wild-type (WT)) and Cd38^–/– mice were dissected in ice-cold HBSS, carefully stripped of their meninges, and digested with 0.25% trypsin for 10 min at 37°C. Trypsinization was stopped by addition of an equal volume of culture medium (DMEM, 10% low endotoxin (10 EU/ml) FCS (HyClone), 100 U/ml penicillin, and 100 µg/ml streptomycin) to which we added 0.02% deoxyribonuclease I. The cells were dispersed into a single-cell level by repeated pipetting, then pelleted and resuspended in culture medium. The cell suspension was then passed through a 100-µm pore mesh. Cells were seeded at a density of 300,000 cells/ml (equivalent to 62,500 cells/cm²) in 6-, 12-, or 96-well plates and cultured at 37°C in humidified 5% CO₂–95% air. Medium was replaced every 4–5 days. These cultures ("mixed glia") reached confluence after 7–10 days and were used between 15 and 20 days after preparation. Microglia were isolated from the mixed glia cultures by a mild trypsinization procedure as previously described (35). Briefly, treatment of the confluent mixed glial cultures with trypsin (0.06%) resulted in detachment of an intact layer of cells containing almost all the astrocytes and leaving behind a highly enriched population of microglia (>98%, as determined by staining with fluorescein-conjugated Griffonia simplicifolia isolectin B4 (Vector Laboratories) and by flow cytometric analysis using the PE-conjugated CD11b Ab (data not shown)). The attached microglia were allowed to recover for 24 h and then were subjected to the different treatments.

Cell viability assays

Primary microglial cultures prepared in 96-well plates as described above were treated with LPS (100 ng/ml) and IFN- (100 U/ml) (hereafter termed LPS/IFN- treatment) for the indicated time periods. In some experiments, the cells were preincubated with 8-Br-cADPR (100 µM), ryanodine (30 µM), N(8-Br-A)D⁺ (100 µM), cycloheximide (CHX (50–100 ng/ml)], or AMD (5–25 ng/ml) for 1–2 h prior, to the addition of LPS/IFN-. In the cross-linking experiments primary microglia were cultured in 24-well plates in the absence or presence of anti-CD38 Abs (clone 90 or NIM-R5) or a rat IgG2a isotype control Ab with or without 5 µg/ml secondary Ab F(ab')₂. On termination of the experiments, the medium from each well was carefully collected and replaced with an equal volume of fresh medium. Cell viability was then determined by the MTT assay. MTT was added to the new medium at a final concentration of 0.5 mg/ml, followed by incubation at 37°C in a CO₂ incubator. After 2 h, the medium was aspirated and dimethyl sulfate (100 µl) was added to the wells. Insoluble crystals were dissolved by mixing and the plates were read on a SpectraMax microELISA plate reader, using a test wavelength of 570 nm and a reference wavelength of 690 nm. Cell death was assessed by monitoring the release of lactate dehydrogenase (LDH) to the culture medium (which was collected at the end of the experiments, see above) using the CytoTox-One Homogeneous Membrane Integrity Assay kit (Promega) according to the manufacturer’s instructions. The LDH signal was read using a test wavelength of 560 nm and a reference wavelength of 590 nm in a Synergy HT MultiDetection Microplate Reader. The viability of the Ba/F₃ cells was assessed as previously described (26). Briefly, cells were plated in 96-well plates (2 x 10⁴ cells/well). After 18 h, primary Abs were added to the culture medium and the cells were grown in the presence or absence of the Abs for additional 24 h. Then MTT was added to the culture medium at a final concentration of 0.5 mg/ml, followed by incubation at 37°C in a CO₂ incubator for 2 h. Acid-isopropanol (100 µl of 0.04 M HCl in isopropanol) was then added to the wells and mixed. The plates were read on a microELISA reader (SpectraMax microplate reader) as described above.

Nitrite quantification

Nitrite, measured as a reflection of NO production in culture supernatants, was assayed using modified Griess reagent. In brief, upon termination of the experiment the culture medium was replaced with an equal volume of new medium, and 50 µl of the removed medium was mixed with an equal volume of Griess reagent in 96-well plates and incubated at room temperature for 15 min. Absorbance at 540 nm was then measured using a microELISA reader (SpectraMax). To normalize the amount of nitrite measured in each well to the amount of cells present in that well, MTT assay was performed after the new medium was added to the cultured cells, as described above.

cADPR measurements

WT and Cd38^–/– primary microglia were washed twice with ice-cold PBS and resuspended on ice with 25 mM sodium phosphate buffer at pH 7.4, homogenized by passing through a 23-g needle (using the 500-µl Bee Stinger Gastight Syringe) and aliquot was removed from each sample to determine the protein content. Perchloric acid (HClO₄) was then added to a final concentration of 0.6 M and homogenates were incubated on ice for 10 min followed by centrifugation (16,000 x g, 10 min, 4°C). Supernatants were transferred to new tubes and the pH was adjusted to pH 7 by K₂CO₃ titration. Homogenates were left on ice for 30 min to enable gas evaporation after which the samples were centrifuged (2,000 x g, 5 min, 4°C) to eliminate salts. Supernatants were collected into new tubes and kept frozen until used.

The measurement of cADPR from samples was then performed essentially as already described for determining cADPR content of synaptosomes (36). The contaminating nucleotides were eliminated by incubation overnight in NaH₂PO₄ at pH 8.0 with a mix of three nucleotide hydrolytic enzymes (nucleotide pyrophosphatase, alkaline phosphatase, and NAD⁺-glycohydrolase). Then, the conversion of cADPR into NAD⁺, in the presence of aplysia ADP-ribosyl cyclase, and the cycling reaction were allowed to proceed. Results were compared with standard solutions of cADPR analyzed in the same experimental conditions.

Immunoblot analysis

Total extracts (30 µg of protein) from each treatment were separated by 12.5% SDS-PAGE and electroblotted onto supported nitrocellulose. Each blot was blocked for 1 h in TBST (10 mM Tris base, 150 mM NaCl, and 0.05% Tween 20) containing 5% fat-free milk, and then incubated with a primary Ab overnight at 4°C. Washing of membranes three times (10 min each) with TBST was followed by incubation for 1 h at room temperature with the appropriate second Ab (goat anti-mouse, donkey anti-rat, or goat anti-rabbit IgG peroxidase conjugate; Jackson ImmunoResearch Laboratories). The blots were developed using the SuperSignal West Pico chemiluminescence kit (Pierce Biotechnology). Each blot was reprobed with β-tubulin to verify that protein was uniformly loaded across the gel.

Assays of GDP-ribosyl cyclase activity

The ectocellular cyclase activity of CD38 was measured using nicotinamide-guanine dinucleotide (NGD⁺) instead of NAD⁺ as a surrogate substrate because the product, cyclic GDP-ribose (cGDPR), is fluorescent and is not susceptible to enzymatic hydrolysis (37). GDP-ribosyl cyclase activity was assayed by incubating NGD⁺ with intact microglial primary cultures or N9 microglial cells. Microglia grown in 96-well plates, untreated or treated with LPS/IFN- for 24 h (primary cultures) or 15 h (N9 cells), were washed once with HBSS and then incubated with HBSS (100 µl/well) at 37°C. After 20 min, NGD⁺ (40 µM) was added to each well and the enzymatic conversion of NGD⁺ to cGDPR was measured fluorometrically by monitoring the increase in fluorescence at 420 nm upon excitation at 300 nm for 10 min, as described previously (32).

Flow cytometry

Microglia were cultured in 6-well plates and treated as indicated. After incubation, the microglia were gently removed from the tissue-culture plates by pipetting, then centrifuged (700 x g, 10 min, 4°C) and incubated (30 min, 4°C) in flow cytometry buffer (PBS containing 1% BSA and 0.05% sodium azide) containing PE-conjugated anti-CD38 (NIM-R5) mAb, PE-conjugated anti CD11b mAb, or isotype-matched control Abs. After washing, Ag expression on 5000 live cells was determined by FACS analysis (FACSort; BD Biosciences) and CellQuest software (BD Biosciences).

Gene expression profiling

RNA extraction, sample preparation, hybridization, and array processing. N9 cells (10⁶ per plate) were washed once with 10 ml of ice-cold PBS, then lysed with 1 ml/plate of TRIzol reagent (Invitrogen) and RNA was prepared according to the manufacturer’s instructions. Total RNA from each sample was used to prepare biotinylated target RNA, with minor modifications from the manufacturer’s recommendations. Briefly, 10 µg of total RNA was used to generate first-strand cDNA by using a T7-linked oligo(dT) primer. After second-strand synthesis, in vitro transcription was performed with biotinylated UTP and CTP (Enzo Diagnostics), resulting in 100-fold amplification of RNA, which was then processed as per manufacturer’s recommendation using an Affymetrix GeneChip Instrument System. Briefly, spike controls were added to 10 µg of fragmented cRNA before overnight hybridization. Arrays were then washed and stained with streptavidin-PE, before being scanned on an Affymetrix GeneChip scanner. Quality and amount of starting RNA were confirmed using an agarose gel. Following scanning, array images were assessed by eye to confirm scanner alignment and the absence of significant bubbles or scratches. 3':5' ratios for GAPDH and β-actin were confirmed to be within acceptable limits range (0.80:0.85 and 1.14:1.2, respectively), and BioB spike controls were found to be present on 100%, with BioC, BioD, and CreX also present in increasing intensity. When scaled to a target intensity of 150 (using Affymetrix MAS 5.0 array analysis software), scaling factors for all arrays were within acceptable limits (0.85–1.06) as were background, Q values, and mean intensities. All experiments were performed using Affymetrix Mouse 430A 2.0 oligonucleotide arrays, as described at www.affymetrix.Com/products/arrays/specific/mgu74.affx. Genes were filtered using Mas 5 algorithm results. A list of 12,827 probe sets of "valid genes," representing probe sets with signals higher than 20 and detected as "present" in at least one sample, was obtained.

Analysis of gene expression data. DNA-microarray data were analyzed using the Expander 3.2 program (38). Data were normalized using Quantile normalization, filtered to include only genes that changed at least 2-fold from control (untreated sample), and standardized (mean 0, variation 1). Analysis yielded a list of 1153 "active genes."

Total RNA isolation, cDNA synthesis, and semiquantitative RT-PCR analysis. Primary microglia were untreated or treated with LPS/IFN- for 10 h. In some experiments, the cells were preincubated for 2 h with 8-Br-cADPR (100 µM). Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen) according to the manufacturer’s instructions. Total RNA (1 µg) was used as template for DNA synthesis, using random decamer primers in a 20-µl reaction volume using the Reverse-iT 1st Strand Synthesis kit (ABgene) according to the manufacturer’s instructions. The cDNA mixture was diluted 1/10 with PCR-grade water. mRNA expression of the indicated genes was measured using the semiquantitative RT-PCR approach. The following primers were used according to the real-time PCR primer and probe database (39): TNF-, sense 5'-GGC TTT CCG AAT TCA CTG GAG-3', antisense 5'-CCC CGG CCT TCC AAA TAA A-3' (target size, 264 bp); IL-12 p40, sense 5'-GGA AGC ACG GCA GCA GAA TA-3', antisense 5'-AAC TTG AGG GAG AAG TAG GAA TGG-3' (target size, 180 bp); IL-6, sense 5'-GAG GAT ACC ACT CCC AAC AGA CC-3', antisense 5'-AAG TGC ATC ATC GTT GTT CAT ACA-3' (target size, 141 bp); NO synthase (NOS)2, sense 5'-CAG CTG GGC TGT ACA AAC CTT-3', antisense 5'-CAT TGG AAG TGA AGC GTT TCG-3' (target size, 95 bp); and GAPDH, sense 5'-CAT GGC CTT CCG TGT TCC TA-3', antisense 5'-ATG CCT GCT TCA CCA CCT TCT-3' (target size, 107 bp). PCR were conducted using 5 µl of cDNA. The resulting PCR products, obtained after 24–26 cycles (in the logarithmic phase of the PCR), were resolved on E-Gel Precast Agarose 2% (Invitrogen). The individual PCR products were scanned and their intensity was determined (ImageMaster). The value of each of the IL-6, IL-12 p40, TNF-, and NOS2 PCR products was then normalized to the intensity of its corresponding housekeeping gene, the GAPDH PCR product.

Measurement of TNF and IL-12 p40 secretion

TNF- and IL-12 p40 secreted into the culture medium were assayed using a DuoSet ELISA kit (R&D Systems) according to the manufacturer’s instructions. Primary microglia grown in 96-well plates (for TNF-) or 24-well plates (for IL-12 p40) were treated with LPS/IFN- for 24 h. In some experiments, the cells were preincubated for 2 h with 8-Br-cADPR (100 µM) or N(8-Br-A)D⁺ (100 µM) before LPS/IFN- treatment. The culture medium was carefully removed from each well, centrifuged at 1000 x g (5 min, 4°C), and then kept frozen at –80°C until used. Cytokine quantity in each well was normalized to either the MTT value (TNF-) or the protein concentration (IL-12 p40) measured in the same well.

Calcium measurements

Intracellular calcium concentrations ([Ca²⁺]_i) were monitored using the Ca²⁺-sensitive fluorescent indicator fura-2 AM, as described (40). Briefly, primary microglial cells were seeded on 18-mm poly-L-lysine-coated circular coverslips in a 12-well plate. Before treatment with LPS/IFN-, cells were left untreated or were treated with LPS/IFN-, in some experiments, after preincubation for 2 h with 8-Br-cADPR (100 µM). After 24 h, the cells were loaded with 2.5 µM fura-2 AM for 60 min at 37°C (in a 5% CO₂ incubator). The fura-2 AM was loaded as a mixture (1:1 in culture medium) with the mild detergent pluronic F-127 (0.05%; used to facilitate loading of the AM ester indicator). Measurements were performed in an external solution (140 mM NaCl, 3 mM KCl, 2 mM CaCl₂, 10 mM HEPES, and 2 mg/ml glucose (pH 7.2–7.4), 300–320 mOsm) at room temperature. For excitation of fura-2, cells were illuminated with two alternating wavelengths, 340 and 380 nm. Excitation was performed and [Ca²⁺]_i values calculated from the ratio (R) of fluorescence recorded at excitation wavelengths of 340 and at 380 nm. Calibrations (by conversion of R340/380 values into molar calcium concentrations) were performed as described (41).

Statistical analysis

Data were expressed as mean values ± SEM. Statistical evaluation was determined by the two-tailed Student t test. A value of p < 0.05 was considered to be statistically significant.

	Results

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Macromolecule synthesis as an essential requirement for microglial AICD

In some apoptotic systems, the death process depends on synthesis of macromolecules. We were therefore interested in examining whether AICD in microglia is dependent on RNA or protein synthesis. AICD was induced by combined treatment with LPS (100 ng/ml) and IFN- (100 U/ml) (LPS/IFN-). N9 cells were treated with LPS/IFN- in the absence or presence of the RNA-synthesis inhibitor AMD or the protein synthesis inhibitor CHX. Determination of cell viability by the MTT assay disclosed that death of the LPS/IFN--treated N9 cells was dose-dependently diminished by both inhibitors (Fig. 1). CHX also inhibited the death of LPS/IFN--treated primary mouse microglia (data not shown). These results suggested that for microglial AICD to occur, some essential gene products need to be synthesized.

View larger version (11K): [in this window] [in a new window]   FIGURE 1. Microglial AICD depends on synthesis of macromolecules. N9 cells were treated without or with LPS/IFN- in the absence or presence of the indicated concentrations of the RNA synthesis inhibitor AMD (A) or the protein synthesis inhibitor CHX (B). Cell viability was determined by the MTT assay as described in Materials and Methods. Survival was assessed in terms of MTT values after treatment, expressed as a percentage of the MTT values without treatment. Values for each treatment are expressed as percentages of the corresponding control (cells untreated or treated with the inhibitor). Values for a given treatment relative to inhibitor untreated cells are defined as significant if: *, p < 0.05 (Student’s t test; n = 3).

DNA-microarray analysis for identification of genes that are preferentially induced by LPS/IFN-

In an attempt to identify the genes whose up-regulated expression is needed for microglial AICD, we used the DNA-microarray technology. In a previous study, we showed that treatment of N9 cells with LPS (100 ng/ml) alone or IFN- (100 U/ml) alone did not substantially affect their viability while the combination of LPS/IFN- induced AICD (26). We therefore prepared total RNA from N9 cells that had been untreated (control) or treated with LPS/IFN-, LPS, or IFN- for 6 h, a time point by which the death gene mRNAs had already been synthesized. This was the earliest time after LPS/IFN- treatment by which the AMD could not rescue the cells from LPS/IFN--induced death and the cell morphology still appeared healthy (data not shown).

The global gene expression profiles in the above-mentioned treatments were recorded by Affymetrix oligonucleotide microarrays. Comparative analysis of the DNA-microarray results from the four different samples identified 1153 probe sets that were changed by at least 2-fold in one or more of the samples. Of all of these probe sets, only 89 genes were preferentially induced by the LPS/IFN- treatment and only 28 of these genes were induced synergistically by the combination of LPS/IFN-. Among the genes identified by this analysis were Nos2 (which encodes the iNOS enzyme that catalyzes NO production) and caspase-11 (Fig. 2A). As NO and caspase-11 are known to be up-regulated and to promote microglial AICD by different pathways (23, 24, 26), it suggested to us that other genes identified in this analysis might also be AICD-promoting candidate genes.

View larger version (21K): [in this window] [in a new window]   FIGURE 2. NOS2, caspase-11, or CD38 expression is preferentially induced by the LPS/IFN- treatment, DNA-microarray and protein expression analysis. N9 cells were treated without (control) or with LPS (100 ng/ml) or IFN- (100 U/ml) or LPS/IFN- (LPS (100 ng/ml) and IFN- (100 U/ml). RNA samples and protein extracts were prepared after 6 and 15 h, respectively. RNA was subjected to gene expression profiling and the results obtained were analyzed as described in Materials and Methods. The protein extracts were analyzed by immunoblotting (A) for the expression of NOS2 and caspase-11, as described in Materials and Methods. The immunoblotting results shown are from a representative experiment for each protein (one of three to five independent experiments). Immunoblots obtained in at least three independent experiments (including the one shown here) were scanned and the intensities of the different proteins were assessed by densitometric analysis. Data are presented as mean values of the intensities obtained for each protein after its normalization to β-tubulin. The data presented are expressed as the ratios of the mean intensities of caspase-11 and NOS2 in LPS-treated, IFN--treated, or control cells to those of LPS/IFN--treated cells (defined as 1 arbitrary unit (AU)). Values shown in the histograms are means ± SEM (bars) (n = 3–5). The gene expression results (obtained from the DNA-microarray analysis) are shown (in parentheses) above each of the corresponding immunoblot results and are expressed for each gene in the same manner as described for the corresponding proteins. For determination of CD38 expression (B), N9 cells were treated as described above for 15 h and then were harvested, stained with PE-conjugated anti-CD38 Abs (PE-CD38), and analyzed by flow cytometry as described in Materials and Methods. The results of a representative experiment for each treatment (one of at least three independent experiments) are shown in the right panels. The empty histogram represents the background staining using an isotype-matched control Ab; the filled area represents CD38 staining. The mean fluorescence intensities (MFIs) for the different treatments of the (at least) three experiments were calculated and their mean values were determined. The left panels present the quantification of the results of three independent experiments (including the one shown here), expressed as CD38 expression values (as determined by the MFIs) in the LPS-, IFN--, or LPS/IFN--treated cells relative to CD38 expression values in the control (defined as 1 AU). Values shown are means ± SEM (bars) (n = 3–4). The gene expression results (obtained from the DNA-microarray analysis) are shown (in brackets) above each of the corresponding flow cytometry results.

CD38 plays an important role in LPS/IFN--induced AICD

One of the 28 genes identified from the DNA microarray analysis as being synergistically induced by LPS/IFN- treatment was Cd38 (Fig. 2B) that encodes the ectoenzyme CD38. CD38 catabolizes its substrate, NAD⁺, to produce metabolites (e.g., cADPR) that increase cytosolic Ca²⁺ concentration. CD38 can also act as a cell surface receptor capable of initiating a signal transduction cascade and cell death in immune cells (34, 42, 43, 44, 45, 46, 47). Therefore, we suspected that it might play an important role also in microglial AICD. To examine this possibility, we first verified the DNA microarray results at the protein expression level. Membrane CD38 expression was determined by FACS analysis. As shown in Fig. 2B, and in agreement with the DNA-microarray results, CD38 protein expression in N9 cells was preferentially induced by the LPS/IFN- treatment relative to treatment with LPS or IFN-. Fig. 3 shows that the LPS/IFN- treatment also induced an increase in membrane CD38 expression in the primary microglia (1.63-fold induction after 24 h) and that as expected, CD38-deficient primary microglia obtained from mice that lack CD38 did not express plasma membrane CD38.

View larger version (15K): [in this window] [in a new window]   FIGURE 3. LPS/IFN- induces CD38 expression in primary microglia. LPS/IFN- induces CD38 expression in the plasma membrane. WT and Cd38–/– primary microglial cultures were grown in the absence or presence of LPS/IFN- for 24 h and the cells were then harvested, stained with PE-conjugated anti-CD38 Abs (PE-CD38), and analyzed for CD38 expression by flow cytometry as described in Materials and Methods. The results of a representative experiment for each genotype (one of three independent experiments) are shown in A. The gray filled histogram represents the background staining obtained with an isotype-matched control Ab, the black filled histogram represents CD38 staining in untreated (control) cells, and the empty histogram represents CD38 staining in LPS/IFN--treated cells. MFIs of the different treatments in three independent experiments in WT microglia were calculated and their mean values were determined. The results of this quantification are presented in B and are expressed as CD38 expression values (as determined by MFIs) in LPS/IFN--treated cells relative to the untreated control (defined as 1 AU). Values shown are means ± SEM (bars) (n = 3); *, p < 0.05 compared with control (Student’s t test).

View larger version (12K): [in this window] [in a new window]   FIGURE 4. CD38 plays an important role in LPS/IFN--induced microglial AICD. WT and Cd38–/– primary microglia were untreated (Con, for 24 h) or treated with LPS/IFN- for the indicated time points. Cell viability was then assessed by monitoring LDH released to the culture medium (A) or by the MTT assay (B). Cell death was defined in terms of the LDH activity in the medium after treatment, expressed as a percentage of the total LDH activity of the cells. Values shown are means ± SEM (bars) (n = 3); *, p < 0.05 compared with the corresponding treatment in Cd38–/– cells as indicated (Student’s t test). The MTT assay and assessment of survival were performed as described in Fig. 1. Survival was expressed as a percentage of the MTT values without treatment. Values shown are means ± SEM (bars) (n = 3); *, p < 0.05 compared with the corresponding treatment in WT cells as indicated (Student’s t test).

View larger version (21K): [in this window] [in a new window]   FIGURE 5. Assessment of CD38 receptor and enzymatic activities in primary microglia. A, CD38 cross-linking does not affect the viability of primary microglia. WT primary microglia were untreated (Control) or treated with LPS/IFN- for 72 h in absence or presence of the indicated concentrations of the primary mAbs: clone 90 (90) or NIM-R5 anti-CD38 Ab or with isotype control Ab (rat IgG2a (IgG)), without (–) or with (+) the secondary anti-rat IgG Ab F(ab')2 (3 µg/ml). Cell death was assessed by monitoring LDH released into the culture medium, and was defined and expressed as described in the legend of Fig. 4. Values shown are means ± SEM (bars) (n = 3). B, CD38 cross-linking induces cell death in CD38exp but not CD38neg Ba/F3 cells. CD38neg and CD38exp Ba/F3 cells were stimulated with the CD38 agonist Abs or isotype control Ab for 24 h. Cell viability was assessed by the MTT assay as described in Materials and Methods. Survival was defined and expressed (left panel) as described in the legend of Fig. 4. Values shown are means ± SEM (bars) (n = 3); *, p < 0.05 compared with isotype control-treated CD38exp Ba/F3 cells (Student’s t test). Expression of CD38 in the CD38neg and CD38exp Ba/F3 cells (right panel). Ba/F3 cells were stained and analyzed for CD38 expression by flow cytometry as described in Fig. 3. The results of a representative experiment for each genotype (one of three independent experiments) are shown. The empty histogram represents the background staining (Mock) obtained with an isotype control Ab, the black filled histogram represents CD38 staining in the CD38exp cells, and the gray filled histogram represents CD38 staining in CD38neg Ba/F3 cells. C, cADPR content is lower in Cd38–/– primary microglia than in WT primary microglia. WT and Cd38–/– primary microglia were untreated (Control) or treated with LPS/IFN- for 24 h and then extracts were prepared from the cells and their cADPR content was determined using the cycling assay (as described in Materials and Methods). Values shown are means ± SEM (bars) (n = 4–5, for untreated and LPS/IFN--treated respectively); *, p < 0.05 compared with the corresponding treatment in Cd38–/– cells (Student’s t test). D, LPS/IFN- treatment induces GDP-ribosyl cyclase activity in WT primary microglia. WT and Cd38–/– primary microglia were grown in the absence (control) or presence of LPS/IFN- for 24 h, and were then subjected to the GDP-ribosyl cyclase activity assay as described in Materials and Methods. Accumulation of the product, cGDPR, was measured fluorometrically. Data presented for WT primary microglia are the fluorescence values obtained after 10 min (no specific fluorescence was detected for Cd38–/– primary microglia). Values shown are means ± SEM (bars) (n = 3).

View larger version (12K): [in this window] [in a new window]   FIGURE 6. The role of cADPR in LPS/IFN- responses. cADPR plays an important role in LPS/IFN--induced microglial AICD. WT and Cd38–/– primary microglia were untreated or treated for 48 h in the absence (–) or presence (+) of the cADPR antagonists 8-Br-cADPR (100 µM) and ryanodine (30 µM) or the CD38 substrate analog N(8-Br-A)D+ (100 µM). Cell death was assessed by monitoring LDH released to the culture medium, and was defined and expressed as described in the legend of Fig. 4. Values shown are means ± SEM (bars) (n = 3); *, p < 0.05 compared with WT microglia treated with LPS/IFN- (Student’s t test).

CD38 is an important player in LPS/IFN--induced NO production

NO and caspase 11 are essential different mediators of LPS/IFN--induced microglial AICD (23, 24, 26). We were therefore interested in examining whether the effect of CD38 on LPS/IFN--induced AICD in primary microglia is mediated via CD38-dependent regulation of NO production, via caspase-11 expression, or both. Examination of the expression of iNOS and caspase-11 in LPS/IFN--treated microglia disclosed that iNOS expression induced by LPS/IFN- in Cd38^–/– primary microglia was markedly lower (by 2.5-fold) than in WT primary microglia. The induction of caspase-11, however, was not affected by CD38 expression (Fig. 7A). These results thus suggest that CD38 controls microglial AICD by promoting NO production (via its effect on iNOS) but not on caspase-11 activation. To further assess if and how CD38 regulates NO production, we examined the effect of CD38 deficiency and cADPR antagonists as well as agonist anti-CD38 Abs on LPS/IFN--induced NO production. Fig. 7B shows that NO production was significantly lower in LPS/IFN--treated Cd38^–/– primary microglia than in WT primary microglia. Fig. 7C shows that the cADPR antagonists 8-Br-cADPR and ryanodine and the CD38 substrate analog N(8-Br-A)D⁺ decreased LPS/IFN--induced NO production in WT primary microglia to similar extents (40% inhibition). Importantly, the reduction in NO production caused by 8-Br-cADPR, ryanodine or by N(8-Br-A)D⁺ was similar to that caused by CD38 deficiency. In contrast to the effect of the cADPR antagonists on NO production, the cross-linking of CD38 did not have any effect on NO production in either LPS/IFN--untreated or treated WT primary microglia (Fig. 7D). These results suggest that in primary microglia CD38 modulates LPS/IFN--induced NO production, and that this effect is mediated, at least in part, by the Ca²⁺-mobilizing cADPR metabolite. Taken together, these results suggest that CD38 plays an important role in the regulation of LPS/IFN--induced NO production and that this effect is mediated via regulation of iNOS induction. In view of the essential role of NO in microglial AICD, these results further support the suggestion that CD38 regulates AICD by promoting NO production. To further assess the relationship between NO production and the effect of CD38 on AICD, we examined the susceptibility of WT and Cd38^–/– primary microglia to external NO by treating them with the NO donor S-nitroso-N-acetylpenicillamine (SNAP). Fig. 7E shows that WT and Cd38^–/– primary microglia exhibited similar susceptibilities to SNAP at all concentrations. This result suggested that the mechanism underlying the enhanced resistance of Cd38^–/– cells to AICD is mediated not by an inhibition of downstream events in the NO-induced apoptotic pathway but rather by attenuation of NO production. Thus, once NO is generated, the sensitivity of Cd38^–/– primary microglia to NO is similar to that of the WT cells.

View larger version (17K): [in this window] [in a new window]   FIGURE 7. Participation of NO but not caspase 11 in the effect of CD38 on microglial AICD. A, iNOS and caspase-11 expression in WT and Cd38–/– primary microglia. Cells were treated without (–) or with LPS/IFN- (+) for 24 h. Protein extracts were then prepared, and iNOS and caspase-11 expression was examined by immunoblot analysis (left panel). The results shown are from a representative experiment (one of three independent experiments). Immunoblots obtained from three independent experiments (including the one shown here) were scanned and the intensities of the different proteins were assessed by densitometric analysis. Data (right panel) are expressed as mean values of the intensities obtained for each protein after its normalization to β-tubulin, and are shown as the values obtained for each protein in LPS/IFN--treated Cd38–/– microglia relative to LPS/IFN--treated WT microglia (defined as 1 AU). B and C, The effect of CD38 and cADPR on NO production. WT and Cd38–/– primary microglia were untreated (control) or treated with LPS/IFN- for the indicated times (B) or for 24 h in the absence (–) or presence (+) of 8-Br-cADPR (100 µM), ryanodine (30 µM), or N(8-Br-A)D+ (100 µM) (C). NO production (Griess reaction) and MTT values were then measured as described in Materials and Methods. Nitrite levels in the medium of each treatment were normalized to the number of live cells in that treatment, as determined by MTT assay, and the results shown in B and C are expressed as the normalized nitrite values in each LPS/IFN- treatment relative to the normalized nitrite values of its corresponding control (24 h, untreated or treated with 8-Br-cADPR, ryanodine or N(8-Br-A)D+ alone; fold increase). Values shown are means ± SEM (bars) (n = 3). *, p < 0.05 compared with the corresponding LPS/IFN--treated Cd38–/– microglia (B) or to LPS/IFN--treated WT microglia (C) (Student’s t test). D, CD38 cross-linking does not affect NO production in LPS/IFN--untreated or treated primary microglia. WT primary microglia were untreated (Control) or treated with LPS/IFN- for 24 h in absence or presence of primary or secondary Ab as described in the legend of Fig. 5A. Nitrite levels in the medium of each treatment were normalized as described in B and C and expressed as the normalized nitrite values in each treatment relative to the normalized nitrite values in primary microglia treated only with LPS/IFN-. Values shown are means ± SEM (bars) (n = 3). E, WT and Cd38–/– primary microglia exhibit similar susceptibilities to SNAP toxicity. WT and Cd38–/– primary microglia were treated with the indicated concentrations of the NO donor SNAP for 24 h, and cell death was then determined by the LDH assay, as described in the legend of Fig. 4A. Values shown are means ± SEM (bars) (n = 3).

CD38 is an important mediator of LPS/IFN--induced microglial activation

Apart from its role in microglial AICD, NO production is an important feature of microglia activation. In view of our results that CD38/cADPR regulates NO production and the notion that elevation of intracellular Ca²⁺ plays a central role in microglial activation (51, 52, 53), we hypothesize that CD38 might act also as a mediator of microglial activation via a cADPR-dependent increase in [Ca²⁺]_i. To test this hypothesis, we examined whether LPS/IFN- increases [Ca²⁺]_i and assessed the effects of CD38 deficiency and the presence of the cADPR antagonist 8-Br-cADPR on any such LPS/IFN--induced increase in [Ca²⁺]_i. Fig. 8 shows that the basal level of [Ca²⁺]_i in Cd38^–/– primary microglia was lower than in WT microglia (75.12 ± 2.9 nM and 85.25 ± 2.19 nM, respectively). Treatment with LPS/IFN- for 24 h increased [Ca²⁺]_i in the WT but not in the Cd38^–/– primary microglia. Furthermore, 8-Br-cADPR completely blocked the LPS/IFN--induced increase in [Ca²⁺]_i.

View larger version (9K): [in this window] [in a new window]   FIGURE 8. LPS/IFN- induces enhancement in [Ca+2]i via the CD38/cADPR pathway. WT and Cd38–/– primary microglia were untreated (–) or treated with LPS/IFN- (+) for 24 h in the absence (–) or presence (+) of the cADPR antagonist 8-Br-cADPR. The cells were loaded with fura-2 AM as described in Materials and Methods. [Ca+2]i levels were determined on the basis of the fluorescence intensity ratio (F340/380). Values shown are means ± SEM (bars) from two to three independent experiments (n = 100–140 cells); *, p < 0.05 relative to untreated WT cells; #, p < 0.05 relative to LPS/IFN--treated WT cells.

View larger version (23K): [in this window] [in a new window]   FIGURE 9. CD38 and cADPR are important players in microglial activation. WT and Cd38–/– primary microglia were grown without (–) or with (+) LPS/IFN- in the absence (–) or presence (+) of 8-Br-cADPR (100 µM), ryanodine (30 µM), or N(8-Br-A)D+ (100 µM), as described in Materials and Methods. Semiquantitative RT-PCR analysis was performed as described in Materials and Methods. PCR products were separated on agarose gel electrophoresis and the results of a representative experiment (one of three to five independent experiments) are shown in A. B, Quantification of the semiquantitative RT-PCR results. Intensities of the PCR products in the different independent experiments (including the one shown) were measured and normalized to GAPDH, as described in Materials and Methods. Results are recorded as the normalized PCR product intensity value in each treatment expressed as a percentage of the value obtained for the LPS/IFN- treatment. Values shown are means ± SEM (bars) (n = 3–5); *, p < 0.05 relative to LPS/IFN- treatment. For analysis of TNF- and IL-12 p40 secretion (C), media were collected and the concentrations of TNF- and IL-12 p40 in the media were determined by ELISA, as described in Materials and Methods. Results are expressed as the amounts of TNF- and IL-12 p40 released to the media, normalized to the number of cells (MTT assay) or protein concentrations, respectively, in the corresponding plates, as described in Materials and Methods. Data are recorded as the normalized values in the different treatments expressed as percentages of the value obtained for the LPS/IFN- treatment in the WT. Values shown are means ± SEM (bars) (n = 4); *, p < 0.05 relative to LPS/IFN- treatment in the WT. D, CD38 cross-linking does not affect TNF- and IL-12 p40 secretion in LPS/IFN--untreated or treated primary microglia. WT primary microglia were untreated (Control) or treated with LPS/IFN- for 72 h in absence or presence of primary or secondary Abs as described in the legend of Fig. 5A. Analysis of TNF- and IL-12 p40 secretion and expression of the data are as described in C. Values shown are means ± SEM (bars) (n = 3).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

Evidence for the participation of CD38 and cADPR in microglial activation and AICD came from the following observations: 1) CD38 expression and enzymatic activity were induced in microglia by treatment with LPS/IFN-. 2) CD38 is the main contributor of cADPR content in both LPS/IFN- treated and untreated primary microglia. 3) CD38 expression in primary microglia was found to be needed for LPS/IFN--induced increase in [Ca²⁺]_i and, at least in part, for induction of various features of microglial activation, including NOS2 induction and NO production, the mRNA induction and protein secretion of TNF- and IL-12 p40, and IL-6 mRNA induction. 4) CD38-deficient primary microglia were more resistant than WT microglia to LPS/IFN--induced AICD. 5) cADPR antagonists inhibited LPS/IFN--induced microglial activation and AICD in WT primary microglia and the extent of this inhibition was similar to that obtained by CD38 deficiency.

The finding that CD38 plays an important role in microglial activation is in line with published studies in which CD38 was assigned as a key regulator of diverse biological processes, particularly in hematopoietic cells. Such processes include response to inflammatory challenges (32, 56), activation of B, T, and NK cells (57, 58, 59, 60), and Ig isotype switching (61). In addition, CD38 was shown to mediate chemotaxis in response to formyl peptide receptor ligands such as fMLF in primary human monocytes and N9 cells (56, 62).

The results showing that CD38 is the main contributor of primary microglia cADPR content are in line with previous studies which showed that CD38 is the main ADP-ribosyl-cyclase in bone marrow myeloid cells (32). However, it was reported that the cADPR content in Cd38^–/– in adult (32, 36) and newborn (36) brain tissues is nearly equivalent to that of the corresponding WT brain tissues and that CD38-deficient neural cells exhibit an ADP-ribosyl cyclase activity (36, 63). These results lead to the suggestion that CD38 may not be the major cADPR-producing enzyme in brain (36). We believe that the likely reason for the discrepancy between our results and the published findings is that the published experiments examined the cADPR content in total brain tissue, whereas microglial cells only represent a small proportion (5–12% in different areas of the brain) (64) of the total cells in the brain. Thus, some of the cell types in the brain, such as the neural cells, express the still unknown cyclase, while other cell types, like microglial cells express CD38.

Mechanism whereby CD38 regulates LPS/IFN--induced microglial activation and AICD

CD38, via its metabolite cADPR, regulates Ca²⁺-mediated signal transduction by increasing the amounts of intracellular-free Ca²⁺ in cells (by promoting Ca²⁺ release from ryanodine receptor-gated stores and by regulating the influx of extracellular Ca²⁺ (32, 65)). It thus seems feasible that CD38 mediates cADPR-associated LPS/IFN- responses by increasing [Ca²⁺]_i. Our results showed that LPS/IFN- indeed induces an increase in [Ca²⁺]_i and that this increase was mediated by CD38 and its metabolite cADPR. Ca²⁺ is also an important mediator of the activation of LPS signaling in primary microglia (51). There is an interesting similarity between the presently observed effects of CD38 deficiency and cADPR antagonists on LPS/IFN--induced primary microglial activation and the previously reported effect of the Ca²⁺ chelator BAPTA (51) on primary microglia activation induced by LPS. According to that report, BAPTA inhibited LPS-induced production of NO and secretion of TNF- and IL-12 in WT primary microglial cultures.

It should be noted that CD38 produces, in addition to cADPR, two other important Ca²⁺-mobilizing metabolites, NAADP⁺ and ADPR (27). NAADP⁺ induces Ca²⁺ release from intracellular lysosomal stores whereas ADPR, the major metabolite produced by CD38, induces Ca²⁺ influx via the transient receptor potential (TRPM2) cation channels (66, 67, 68). Our data does not exclude the possibility that these additional metabolites generated by CD38 may also play a role in regulating microglial cell activation or AICD. In addition, we cannot exclude the possibility that the loss of CD38 alters NAD⁺ homeostasis (69, 70), which may lead in turn to "disregulated" activity of other NAD⁺-utilizing enzymes such as ecto-ADP-ribosyltransferases (31) and poly(ADP-ribose) polymerases. Although NAD dysregulation or production of the other metabolites produced by CD38 might also participate in LPS/IFN--mediated microglial activation and AICD, our data clearly indicate that cADPR is important in these processes. Furthermore, our experiments using the CD38 substrate analog N(8-Br-A)D⁺ also strongly suggested that CD38 mediates effects through an enzyme-dependent mechanism and not by functioning as a cell surface signaling receptor as reported in hematopoietic cells (34, 43). This conclusion is further supported by our results which show that in primary microglia, the cross-linking of CD38 using two different agonist anti-CD38 Abs did not affect either the viability, NO production or cytokine secretion by LPS/IFN--treated or untreated WT microglia.

Our results, point to a regulatory role for CD38 in LPS/IFN--induced microglial activation, and are in line with studies that suggested that cADPR has an important function in mediating the effects of LPS (71) and of fMLF (56) in the N9 cell line. In our study, however, the role of CD38 in LPS/IFN--induced microglial activation was demonstrated directly, and this CD38 effect was shown to occur in primary microglial cultures. The former finding is of great interest because it is becoming increasingly evident that microglia do not constitute a single, uniform cell population but rather comprise a family of cells (72). It is therefore of the utmost importance to study the characteristics of microglial activation in primary microglial cultures.

It should be noted that although microglial activation and AICD were attenuated by CD38 deficiency and cADPR antagonists, the inhibition was not complete. With regard to microglial AICD, it is known that this process is mediated by several pathways and molecules (23, 26). CD38 is thus one of several molecules whose induced expression and combined action culminates in microglial cell death. Similarly, additional signaling systems beside CD38/cADPR are likely to participate in the induction of microglial activation by LPS/IFN-. Indeed, we found that CD38/cADPR does not regulate caspase 11 expression, an important mediator of the AICD pathway. Furthermore, data from others have shown that enhancement of [Ca ²⁺]_i alone did not induce NO production or cytokine secretion in primary microglia (51). Thus, it is clear that the CD38/cADPR-dependent signaling pathway is only one of perhaps many pathways that contribute to microglial activation and AICD.

Linking microglial activation to AICD

Studies by our group (26) and by others (23, 24) have shown that NO is an essential mediator of LPS/IFN--induced AICD. Our present finding that CD38 promotes the LPS/IFN--induced production of NO in primary microglia suggests that the effect of CD38 on microglial AICD is mediated via this CD38-mediated regulation of iNOS induction and NO production. This likelihood is further supported by the observation that CD38 does not affect caspase-11 expression, also an essential step in LPS/IFN--induced AICD (23). Moreover, we did not observe any substantial differences in the expression levels of key apoptotic proteins (Bcl-x_L, MCl-1, Bid, Bim caspase-1, and caspase-7) between CD38-expressing and CD38-deficient primary microglia (data not shown). Furthermore, in contrast to the observed resistance of CD38-deficient primary microglia to LPS/IFN-, these cells were as sensitive as CD38-expressing microglia to NO donor toxicity and to the well-established apoptotic trigger staurosporine (data not shown). Taken together, these results suggest that the lack of CD38 does not endow the cells with a general resistance to apoptosis but rather confers a specific resistance to LPS/IFN--induced AICD, probably by reducing the amount of NO. Our results further suggest that CD38 links activation to AICD by controlling the amount of NO that the cells produce.

Activated microglia are present in almost all neurological diseases, where they may promote both beneficial and harmful effects (72). Our demonstration of the important role of CD38 in microglial activation and AICD suggests that CD38, via its regulatory effect on microglial functions and fate, might play an important role in acute and chronic brain derangements, and hence that manipulation of CD38 expression and/or activity might represent a useful future approach for treating neurological diseases. Toward that aim, it will be necessary to extend the present in vitro study to systems in vivo, and to study microglial activation and brain susceptibility to injury and inflammation in CD38-deficient mice after various brain insults. Such studies are currently in progress in our laboratory.

	Acknowledgments

 
We are grateful to Shirley Smith for excellent editorial assistance. We thank Dr. Uri Ashery (Tel Aviv University, Tel Aviv, Israel) for help with calcium measurements and Dr. Norman Oppenheimer (University of California, San Francisco, CA) for providing N(8-Br-A)D⁺.

	Disclosures

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The authors have no financial conflict of interest.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by the Israel Science Foundation (643/02), the Adams Super-Center for Brain Research, and the National Institutes of Health (R01-AI-057996; to F.E.L.).

² Address correspondence and reprint requests to Dr. Reuven Stein, Department of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, 69978 Ramat Aviv, Israel. E-mail address: reuvens{at}post.tau.ac.il

³ Abbreviations used in this paper: AICD, activation-induced cell death; cADPR, cyclic ADP-ribose; AMD, actinomycin D; iNOS, inducible NO synthetase; WT, wild type; N(8-Br-A)D⁺, nicotinamide 8-bromoadenine dinucleotide; CHX, cycloheximide; LDH, lactate dehydrogenase; NGD, nicotinamide-guanine dinucleotide; cGDPR, cyclic GDP-ribose; NOS, NO synthase; [Ca²⁺]_i, intracellular calcium concentration; SNAP, S-nitroso-N-acetylpenicillamine.

Received for publication May 31, 2007. Accepted for publication April 21, 2008.

	References

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 

1. Raivich, G., M. Bohatschek, C. U. Kloss, A. Werner, L. L. Jones, G. W. Kreutzberg. 1999. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res. Rev. 30: 77-105. [Medline]
2. Streit, W. J., J. R. Conde, S. E. Fendrick, B. E. Flanary, C. L. Mariani. 2005. Role of microglia in the central nervous system’s immune response. Neurol. Res. 27: 685-691. [Medline]
3. Roy, A., Y. K. Fung, X. Liu, K. Pahan. 2006. Up-regulation of microglial CD11b expression by nitric oxide. J. Biol. Chem. 281: 14971-14980. [Abstract/Free Full Text]
4. Weiner, H. L., D. Frenkel. 2006. Immunology and immunotherapy of Alzheimer’s disease. Nat. Rev. Immunol. 6: 404-416. [Medline]
5. Batchelor, P. E., G. T. Liberatore, J. Y. Wong, M. J. Porritt, F. Frerichs, G. A. Donnan, D. W. Howells. 1999. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 19: 1708-1716. [Abstract/Free Full Text]
6. Schwartz, M.. 2003. Macrophages and microglia in central nervous system injury: are they helpful or harmful?. J. Cereb. Blood Flow Metab. 23: 385-394. [Medline]
7. Paresce, D. M., R. N. Ghosh, F. R. Maxfield. 1996. Microglial cells internalize aggregates of the Alzheimer’s disease amyloid β-protein via a scavenger receptor. Neuron 17: 553-565. [Medline]
8. Boje, K. M., P. K. Arora. 1992. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res. 587: 250-256. [Medline]
9. Chao, C. C., S. Hu, T. W. Molitor, E. G. Shaskan, P. K. Peterson. 1992. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J. Immunol. 149: 2736-2741. [Abstract]
10. Chao, C. C., S. Hu, P. K. Peterson. 1995. Glia, cytokines, and neurotoxicity. Crit. Rev. Neurobiol. 9: 189-205. [Medline]
11. McGeer, E. G., P. L. McGeer. 1998. The importance of inflammatory mechanisms in Alzheimer disease. Exp. Gerontol. 33: 371-378. [Medline]
12. Halliday, G., S. R. Robinson, C. Shepherd, J. Kril. 2000. Alzheimer’s disease and inflammation: a review of cellular and therapeutic mechanisms. Clin. Exp. Pharmacol. Physiol. 27: 1-8. [Medline]
13. Kim, Y. S., T. H. Joh. 2006. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp. Mol. Med. 38: 333-347. [Medline]
14. Beschorner, R., T. D. Nguyen, F. Gozalan, I. Pedal, R. Mattern, H. J. Schluesener, R. Meyermann, J. M. Schwab. 2002. CD14 expression by activated parenchymal microglia/macrophages and infiltrating monocytes following human traumatic brain injury. Acta Neuropathol. 103: 541-549. [Medline]
15. Koshinaga, M., Y. Katayama, M. Fukushima, H. Oshima, T. Suma, T. Takahata. 2000. Rapid and widespread microglial activation induced by traumatic brain injury in rat brain slices. J. Neurotrauma 17: 185-192. [Medline]
16. Streit, W. J., S. A. Walter, N. A. Pennell. 1999. Reactive microgliosis. Prog. Neurobiol. 57: 563-581. [Medline]
17. Kreutzberg, G. W.. 1996. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19: 312-318. [Medline]
18. Dihne, M., F. Block, H. Korr, R. Topper. 2001. Time course of glial proliferation and glial apoptosis following excitotoxic CNS injury. Brain Res. 902: 178-189. [Medline]
19. Vela, J. M., A. Yanez, B. Gonzalez, B. Castellano. 2002. Time course of proliferation and elimination of microglia/macrophages in different neurodegenerative conditions. J. Neurotrauma 19: 1503-1520. [Medline]
20. Bonetti, B., J. Pohl, Y. L. Gao, C. S. Raine. 1997. Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. J. Immunol. 159: 5733-5741. [Abstract]
21. Gehrmann, J., R. B. Banati. 1995. Microglial turnover in the injured CNS: activated microglia undergo delayed DNA fragmentation following peripheral nerve injury. J. Neuropathol. Exp. Neurol. 54: 680-688. [Medline]
22. White, C. A., P. A. McCombe, M. P. Pender. 1998. Microglia are more susceptible than macrophages to apoptosis in the central nervous system in experimental autoimmune encephalomyelitis through a mechanism not involving Fas (CD95). Int. Immunol. 10: 935-941. [Abstract/Free Full Text]
23. Lee, J., J. Hur, P. Lee, J. Y. Kim, N. Cho, S. Y. Kim, H. Kim, M. S. Lee, K. Suk. 2001. Dual role of inflammatory stimuli in activation-induced cell death of mouse microglial cells. Initiation of two separate apoptotic pathways via induction of interferon regulatory factor-1 and caspase-11. J. Biol. Chem. 276: 32956-32965. [Abstract/Free Full Text]
24. Lee, P., J. Lee, S. Kim, M. S. Lee, H. Yagita, S. Y. Kim, H. Kim, K. Suk. 2001. NO as an autocrine mediator in the apoptosis of activated microglial cells: correlation between activation and apoptosis of microglial cells. Brain Res. 892: 380-385. [Medline]
25. Liu, B., K. Wang, H. M. Gao, B. Mandavilli, J. Y. Wang, J. S. Hong. 2001. Molecular consequences of activated microglia in the brain: overactivation induces apoptosis. J. Neurochem. 77: 182-189. [Medline]
26. Mayo, L., R. Stein. 2007. Characterization of LPS and interferon- triggered activation-induced cell death in N9 and primary microglial cells: induction of the mitochondrial gateway by nitric oxide. Cell Death Differ. 14: 183-186. [Medline]
27. Schuber, F., F. E. Lund. 2004. Structure and enzymology of ADP-ribosyl cyclases: conserved enzymes that produce multiple calcium mobilizing metabolites. Curr. Mol. Med. 4: 249-261. [Medline]
28. Funaro, A., E. Ferrero, K. Mehta, F. Malavasi. 2000. Schematic portrait of human CD38 and related molecules. Chem. Immunol. 75: 256-273. [Medline]
29. Fliegert, R., A. Gasser, A. H. Guse. 2007. Regulation of calcium signalling by adenine-based second messengers. Biochem. Soc. Trans. 35: 109-114. [Medline]
30. Cockayne, D. A., T. Muchamuel, J. C. Grimaldi, H. Muller-Steffner, T. D. Randall, F. E. Lund, R. Murray, F. Schuber, M. C. Howard. 1998. Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses. Blood 92: 1324-1333. [Abstract/Free Full Text]
31. Krebs, C., S. Adriouch, F. Braasch, W. Koestner, E. H. Leiter, M. Seman, F. E. Lund, N. Oppenheimer, F. Haag, F. Koch-Nolte. 2005. CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins. J. Immunol. 174: 3298-3305. [Abstract/Free Full Text]
32. Partida-Sanchez, S., D. A. Cockayne, S. Monard, E. L. Jacobson, N. Oppenheimer, B. Garvy, K. Kusser, S. Goodrich, M. Howard, A. Harmsen, et al 2001. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat. Med. 7: 1209-1216. [Medline]
33. Righi, M., L. Mori, G. De Libero, M. Sironi, A. Biondi, A. Mantovani, S. D. Donini, P. Ricciardi-Castagnoli. 1989. Monokine production by microglial cell clones. Eur. J. Immunol. 19: 1443-1448. [Medline]
34. Lund, F. E., H. Muller-Steffner, H. Romero-Ramirez, M. E. Moreno-Garcia, S. Partida-Sanchez, M. Makris, N. J. Oppenheimer, L. Santos-Argumedo, F. Schuber. 2006. CD38 induces apoptosis of a murine pro-B leukemic cell line by a tyrosine kinase-dependent but ADP-ribosyl cyclase- and NAD glycohydrolase-independent mechanism. Int. Immunol. 18: 1029-1042. [Abstract/Free Full Text]
35. Saura, J., J. M. Tusell, J. Serratosa. 2003. High-yield isolation of murine microglia by mild trypsinization. Glia 44: 183-189. [Medline]
36. Ceni, C., N. Pochon, M. Villaz, H. Muller-Steffner, F. Schuber, J. Baratier, M. De Waard, M. Ronjat, M. J. Moutin. 2006. The CD38-independent ADP-ribosyl cyclase from mouse brain synaptosomes: a comparative study of neonate and adult brain. Biochem. J. 395: 417-426. [Medline]
37. Graeff, R. M., T. F. Walseth, K. Fryxell, W. D. Branton, H. C. Lee. 1994. Enzymatic synthesis and characterizations of cyclic GDP-ribose: a procedure for distinguishing enzymes with ADP-ribosyl cyclase activity. J. Biol. Chem. 269: 30260-30267. [Abstract/Free Full Text]
38. Shamir, R., A. Maron-Katz, A. Tanay, C. Linhart, I. Steinfeld, R. Sharan, Y. Shiloh, R. Elkon. 2005. EXPANDER–an integrative program suite for microarray data analysis. BMC Bioinformatics 6: 232[Medline]
39. Pattyn, F., P. Robbrecht, A. De Paepe, F. Speleman, J. Vandesompele. 2006. RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Res. 34: D684-D688. [Abstract/Free Full Text]
40. Yizhar, O., U. Matti, R. Melamed, Y. Hagalili, D. Bruns, J. Rettig, U. Ashery. 2004. Tomosyn inhibits priming of large dense-core vesicles in a calcium-dependent manner. Proc. Natl. Acad. Sci. USA 101: 2578-2583. [Abstract/Free Full Text]
41. Grynkiewicz, G., M. Poenie, R. Y. Tsien. 1985. A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260: 3440-3450. [Abstract/Free Full Text]
42. Lee, H. C.. 2000. Enzymatic functions and structures of CD38 and homologs. Chem. Immunol. 75: 39-59. [Medline]
43. Lund, F. E., D. A. Cockayne, T. D. Randall, N. Solvason, F. Schuber, M. C. Howard. 1998. CD38: a new paradigm in lymphocyte activation and signal transduction. Immunol. Rev. 161: 79-93. [Medline]
44. Lund, F. E., H. M. Muller-Steffner, N. Yu, C. D. Stout, F. Schuber, M. C. Howard. 1999. CD38 signaling in B lymphocytes is controlled by its ectodomain but occurs independently of enzymatically generated ADP-ribose or cyclic ADP-ribose. J. Immunol. 162: 2693-2702. [Abstract/Free Full Text]
45. Gregorini, A., M. Tomasetti, C. Cinti, D. Colomba, S. Colomba. 2006. CD38 expression enhances sensitivity of lymphoma T and B cell lines to biochemical and receptor-mediated apoptosis. Cell Biol. Int. 30: 727-732. [Medline]
46. Kumagai, M., E. Coustan-Smith, D. J. Murray, O. Silvennoinen, K. G. Murti, W. E. Evans, F. Malavasi, D. Campana. 1995. Ligation of CD38 suppresses human B lymphopoiesis. J. Exp. Med. 181: 1101-1110. [Abstract/Free Full Text]
47. Silvennoinen, O., H. Nishigaki, A. Kitanaka, M. Kumagai, C. Ito, F. Malavasi, Q. Lin, M. E. Conley, D. Campana. 1996. CD38 signal transduction in human B cell precursors: rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C- and phosphatidylinositol 3-kinase. J. Immunol. 156: 100-107. [Abstract]
48. Rizzuto, R., P. Pinton, D. Ferrari, M. Chami, G. Szabadkai, P. J. Magalhaes, F. Di Virgilio, T. Pozzan. 2003. Calcium and apoptosis: facts and hypotheses. Oncogene 22: 8619-8627. [Medline]
49. Guse, A. H.. 2005. Second messenger function and the structure-activity relationship of cyclic adenosine diphosphoribose (cADPR). FEBS J. 272: 4590-4597. [Medline]
50. White, T. A., M. S. Kannan, T. F. Walseth. 2003. Intracellular calcium signaling through the cADPR pathway is agonist specific in porcine airway smooth muscle. FASEB J. 17: 482-484. [Abstract/Free Full Text]
51. Hoffmann, A., O. Kann, C. Ohlemeyer, U. K. Hanisch, H. Kettenmann. 2003. Elevation of basal intracellular calcium as a central element in the activation of brain macrophages (microglia): suppression of receptor-evoked calcium signaling and control of release function. J. Neurosci. 23: 4410-4419. [Abstract/Free Full Text]
52. Moller, T.. 2002. Calcium signaling in microglial cells. Glia 40: 184-194. [Medline]
53. Farber, K., H. Kettenmann. 2006. Functional role of calcium signals for microglial function. Glia 54: 656-665. [Medline]
54. Howard, M., J. C. Grimaldi, J. F. Bazan, F. E. Lund, L. Santos-Argumedo, R. M. Parkhouse, T. F. Walseth, H. C. Lee. 1993. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 262: 1056-1059. [Abstract/Free Full Text]
55. Lee, H. C.. 2005. Nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling. J. Biol. Chem. 280: 33693-33696. [Free Full Text]
56. Partida-Sanchez, S., P. Iribarren, M. E. Moreno-Garcia, J. L. Gao, P. M. Murphy, N. Oppenheimer, J. M. Wang, F. E. Lund. 2004. Chemotaxis and calcium responses of phagocytes to formyl peptide receptor ligands is differentially regulated by cyclic ADP ribose. J. Immunol. 172: 1896-1906. [Abstract/Free Full Text]
57. Funaro, A., G. C. Spagnoli, C. M. Ausiello, M. Alessio, S. Roggero, D. Delia, M. Zaccolo, F. Malavasi. 1990. Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. J. Immunol. 145: 2390-2396. [Abstract]
58. Sconocchia, G., J. A. Titus, A. Mazzoni, A. Visintin, F. Pericle, S. W. Hicks, F. Malavasi, D. M. Segal. 1999. CD38 triggers cytotoxic responses in activated human natural killer cells. Blood 94: 3864-3871. [Abstract/Free Full Text]
59. Mallone, R., A. Funaro, M. Zubiaur, G. Baj, C. M. Ausiello, C. Tacchetti, J. Sancho, C. Grossi, F. Malavasi. 2001. Signaling through CD38 induces NK cell activation. Int. Immunol. 13: 397-409. [Abstract/Free Full Text]
60. Lund, F. E., N. W. Solvason, M. P. Cooke, A. W. Health, J. C. Grimaldi, R. M. Parkhouse, C. C. Goodnow, M. C. Howard. 1995. Signaling through murine CD38 is impaired in antigen receptor-unresponsive B cells. Eur. J. Immunol. 25: 1338-1345. [Medline]
61. Yasue, T., M. Baba, S. Mori, C. Mizoguchi, S. Uehara, K. Takatsu. 1999. IgG1 production by sIgD⁺ splenic B cells and peritoneal B-1 cells in response to IL-5 and CD38 ligation. Int. Immunol. 11: 915-923. [Abstract/Free Full Text]
62. Pfister, M., A. Ogilvie, C. P. da Silva, A. Grahnert, A. H. Guse, S. Hauschildt. 2001. NAD degradation and regulation of CD38 expression by human monocytes/macrophages. Eur. J. Biochem. 268: 5601-5608. [Medline]
63. Ceni, C., H. Muller-Steffner, F. Lund, N. Pochon, A. Schweitzer, M. De Waard, F. Schuber, M. Villaz, M. J. Moutin. 2003. Evidence for an intracellular ADP-ribosyl cyclase/NAD⁺-glycohydrolase in brain from CD38-deficient mice. J. Biol. Chem. 278: 40670-40678. [Abstract/Free Full Text]
64. Lawson, L. J., V. H. Perry, P. Dri, S. Gordon. 1990. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39: 151-170. [Medline]
65. Guse, A. H., C. P. da Silva, I. Berg, A. L. Skapenko, K. Weber, P. Heyer, M. Hohenegger, G. A. Ashamu, H. Schulze-Koops, B. V. Potter, G. W. Mayr. 1999. Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. Nature 398: 70-73. [Medline]
66. Sano, Y., K. Inamura, A. Miyake, S. Mochizuki, H. Yokoi, H. Matsushime, K. Furuichi. 2001. Immunocyte Ca²⁺ influx system mediated by LTRPC2. Science 293: 1327-1330. [Abstract/Free Full Text]
67. Perraud, A. L., A. Fleig, C. A. Dunn, L. A. Bagley, P. Launay, C. Schmitz, A. J. Stokes, Q. Zhu, M. J. Bessman, R. Penner, et al 2001. ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. Nature 411: 595-599. [Medline]
68. Hara, Y., M. Wakamori, M. Ishii, E. Maeno, M. Nishida, T. Yoshida, H. Yamada, S. Shimizu, E. Mori, J. Kudoh, et al 2002. LTRPC2 Ca²⁺-permeable channel activated by changes in redox status confers susceptibility to cell death. Mol. Cell 9: 163-173. [Medline]
69. Young, G. S., E. Choleris, F. E. Lund, J. B. Kirkland. 2006. Decreased cADPR and increased NAD⁺ in the CD38^–/– mouse. Biochem. Biophys. Res. Commun. 346: 188-192. [Medline]
70. Aksoy, P., T. A. White, M. Thompson, E. N. Chini. 2006. Regulation of intracellular levels of NAD: a novel role for CD38. Biochem. Biophys. Res. Commun. 345: 1386-1392. [Medline]
71. Franco, L., N. Bodrato, I. Moreschi, C. Usai, S. Bruzzone, S. Scarfi, E. Zocchi, A. De Flora. 2006. Cyclic ADP-ribose is a second messenger in the lipopolysaccharide-stimulated activation of murine N9 microglial cell line. J. Neurochem. 99: 165-176. [Medline]
72. Schwartz, M., O. Butovsky, W. Bruck, U. K. Hanisch. 2006. Microglial phenotype: is the commitment reversible?. Trends Neurosci. 29: 68-74. [Medline]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mayo, L. Articles by Stein, R. Search for Related Content PubMed PubMed Citation Articles by Mayo, L. Articles by Stein, R.